GlobeNewswire

NEP Group Acquires SIS LIVE

Del

LONDON, Oct. 09, 2018 (GLOBE NEWSWIRE) -- NEP Group, a worldwide outsourced technical production partner supporting premier content producers of live sports and entertainment, announced today its acquisition of SIS LIVE Limited, a leading provider of connectivity services and a subsidiary of UK-based Sports Information Services (“SIS”). The acquisition complements NEP’s Broadcast Services and Media Solutions businesses, strengthening the company’s support of live sports, broadcast and entertainment clients across the UK, Europe and worldwide. The addition is also consistent with NEP’s stated strategy to grow its Media Solutions segment, and connectivity capabilities are critical to NEP delivering a full suite of managed services that enable NEP’s clients to make, manage and show the world their content.

“We are excited to bring the wealth of knowledge of SIS LIVE’s leadership team and the company’s talented staff into the NEP Worldwide Network,” said Stephen Jenkins, President of NEP UK & Ireland. “With SIS LIVE, NEP will be able to offer additional and enhanced connectivity capabilities critical to delivering the best managed service and solutions to our clients. And, it’s a great fit culturally for both of our companies. A win for clients and our teams all around.”

With two dedicated network operations centres providing 24/7 service monitoring and management, 17 antennas across two geographically diverse teleports, over 150 connected venues, a large fibre and satellite hybrid fleet and fully managed services offerings, SIS LIVE is a leading provider of global critical connectivity services delivering content to millions of viewers worldwide. Their core Anylive® fibre network has over 150 access points at major sporting venues, entertainment complexes and other connectivity centres supporting clients such as BBC, ITV, ITN, Sky Sports, SIS, ARC, TRP and Tata.

Following a short transition period, SIS LIVE will become NEP Connect, which will serve clients globally as part of the NEP Worldwide Network and go to market under the NEP brand. SIS LIVE’s current leadership team will continue to run the business under the direction of David Meynell, Managing Director, who will report into the NEP UK & Ireland division.

“We have worked with NEP for a number of years and have been impressed by their technical innovation and consistent, superior service to their clients,” said David Meynell, Managing Director of SIS LIVE. “I’m extremely proud of all we’ve accomplished at SIS LIVE and pleased that combining talents and resources with a company like NEP will take our business to the next level.”

SIS CEO Richard Ames added: “It was immediately apparent during the sale process that NEP Group has significant opportunity to grow its Media Solutions segment, and SIS LIVE has the infrastructure, people and services that support that strategic objective. We look forward to continuing to work with SIS LIVE as a long-term supply partner.”

To learn more about NEP and its solutions, visit https://www.nepgroup.com. To learn more about SIS LIVE’s connectivity services, visit https://www.sislive.tv.
###

About NEP
For over 30 years, NEP has been a worldwide outsourced technical production partner supporting premier content producers of live sports, entertainment, music and corporate events. Our services include remote production, studio production, audio visual solutions, host broadcast support, premium playout, post production and innovative software-based media management solutions. NEP’s 3,500+ employees are driven by a passion for superior service and a focus on technical innovation. Together, we have supported productions in 87 countries on all seven continents.

NEP is headquartered in the United States and has operations in 24 countries, including significant operations in the UK and Ireland. Learn more at nepgroup.com.

About SIS LIVE
SIS LIVE has been delivering critical media content since 1989. The company’s rapidly growing international fibre network, Anylive® connects over 150 locations including broadcasters, major switching centres, channel aggregators, sports and entertainment venues.  SIS LIVE operates two Network Operation Centres located in the UK, collocated with SIS LIVE teleports which supply extensive satellite facilities to complete the connectivity offering.  The company provides a full range of broadcast services from UHD to low bit rate streaming with data and audio transmission services also available.  This comprehensive fibre and satellite infrastructure forms a cohesive and robust portfolio, broadcasting over 200 hours of live transmissions worldwide every day supporting multiple contracted and occasional use events.

Attachment

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CESTPressemelding

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad